Shots:

• Health Canada has approved Brenzys for new indications that include adults & pediatric patients (4-17yrs.) with PsO who are candidates for systemic therapy/ phototherapy- adult patients with PsA- and patients aged 4-17yrs. with JIA
• The clinical efficacy and safety studies conducted in patients with RA demonstrate clinical comparability between Brenzys and the reference product. The extrapolation of these data supports the use of Brenzys in AS
• Brenzys is a biosimilar referencing Enbrel- which is approved for use for PsO- PsA- and JIA in Canada. Brenzys received its first Health Canada approval in 2016 for the mod. to sev. RA in adults and AS and is administered via injection under the skin and should be used under the guidance and supervision of a physician

­ Ref: Newswire Canada | Image: Merck